What is the official ID of this bill?

The official print number for this legislation is HR 2868.

When did the legislative process begin?

The process officially started on 2021-04-28.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/hr2868/BILLS-117hr2868ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Who is the primary sponsor?

The primary sponsor is Rep. Butterfield, G. K. [D-NC-1].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Analysis and Potential Impact of HR 2868

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Medicaid Generic Drugs: No Extra Rebates for Low-Cost Medicines.

Q: What are the main provisions?

Key points include: The bill concerns generic (noninnovator) drugs in the Medicaid program. Manufacturers will not be required to pay additional rebates for drugs with a unit price less than $1. These changes are set to take effect from January 1, 2022. The goal is to ensure that low-cost generic drugs remain available within the Medicaid program.

This bill aims to prevent additional rebates for certain low-cost generic drugs within the Medicaid program. It means manufacturers of these drugs will not have to pay extra rebates if the unit price of the drug is less than $1. The goal is to maintain the availability of these medicines in the market, potentially affecting price stability and access to treatment for Medicaid beneficiaries.

Key points

The bill concerns generic (noninnovator) drugs in the Medicaid program.

Manufacturers will not be required to pay additional rebates for drugs with a unit price less than $1.

These changes are set to take effect from January 1, 2022.

The goal is to ensure that low-cost generic drugs remain available within the Medicaid program.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Protecting Access to Affordable Medicines Act of 2021

Print number: HR 2868

Sponsor: Rep. Butterfield, G. K. [D-NC-1]

Process start date: 2021-04-28

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Medicaid Generic Drugs: No Extra Rebates for Low-Cost Medicines.

Key Questions about Medicaid Generic Drugs: No Extra Rebates for Low-Cost Medicines.